samedan logo
 
 
 
spacer
home > ebr > spring 2018 > sudden impact
PUBLICATIONS
European Biopharmaceutical Review

Sudden Impact

The development of biological therapeutics such as humanised antibodies has led to remarkable clinical benefits in many indications. Despite this success, the induction of anti-drug antibodies (ADAs) due to the potential immunogenicity of these therapeutics remains a significant challenge to the successful development of biotherapeutics.

The decades that followed the approval of the first biotherapeutic (Insulin, 1982) have seen a dramatic increase in both the number and rate of approvals. Biologics now account for over 30% of licensed pharmaceutical products and over 25% of the new drugs approved by The Center for Drug Evaluation and Research in 2015. For monoclonal antibodies (mAbs) alone, since the commercialisation of the first mAb in 1986, this class of product has increased significantly. By 2014, 47 mAb products had been approved in the US and Europe. At the current approval rate, it can be anticipated that approximately 70 mAb products will be on the market by 2020, with combined worldwide sales of nearly US$125 billion (1).

Despite this success, biologics can elicit immunological responses when administered to patients, which can affect their safety and efficacy. These side effects fall into two categories: pharmacological (largely predictable adverse reactions resulting from the interaction between the biologic and its target) and non-pharmacological. Non-pharmacological adverse events contain immunotoxicity, which includes both immuneresponseand non-immune response-mediated reactions.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Gary Bembridge is Senior Director of scientific affairs (immunology) at Abzena. Since joining the company in 2013, he has managed business development activities associated with immunological responses to biotherapeutics, ensuring that immunogenicity assessment and bespoke immunological studies are tailored to partnersí needs. Prior to this, Gary worked at Huntingdon Life Sciences (Envigo) as a Biopharmaceutical Product Development Manager and shared responsibility for designing safety studies and nonclinical development programmes for all biologics, providing scientific support and advice to the immunology department. He completed his PhD at the University of Bristol, UK, and the Department of Veterinary Medicine.

Dr Karen Hills is in marketing and business development at Abzena in Cambridge, UK. She is a consultant in pharma/biopharma business development and marketing. Since joining Abzena, Karen has focused on marketing across the areas of cell-line development, chemistry manufacturing, and immunology. Karen has a PhD in molecularb from Cambridge University, UK, and an MBA from the London Business School, UK. Her background includes sales, marketing, and business development for companies ranging from start-up biotech to Big Pharma.
spacer
Dr Gary Bembridge
spacer
spacer
spacer
Dr Karen Hills
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

IONTAS announces a new collaboration to identify novel immunotherapy targets

Cambridge, UK, 07 May 2020: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, today announced it has entered into a collaboration agreement with Inotrem, a specialist in immunotherapy for acute and chronic inflammatory syndromes. As part of the agreement, IONTAS will apply its Mammalian Display technology to identify antibodies involved in the TREM-1 pathway.
More info >>

White Papers

High-tech Packaging for High-tech Medicine

West Pharmaceutical Services, Inc.

As more biologics and biosimilars come on to the global pharmaceutical market, they can and will present unique packaging and containment challenges. For materials that are sensitive to glass or that may require larger-dose volumes or custom configurations, cyclic olefin polymers may offer a solution. These novel materials for drug container closure systems can provide a needed alternative to traditional glass containment systems for advanced therapeutics.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement